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A recent study reported an association between the brain natriuretic peptide (BNP) promoter T-381C poly-
morphism (rs198389) and protection against type 2 diabetes (T2D). As replication in several studies is man-
datory to confirm genetic results, we analyzed the T-381C polymorphism in seven independent case–control
cohorts and in 291 T2D-enriched pedigrees totalling 39 557 subjects of European origin. A meta-analysis of
the seven case–control studies (n 5 39 040) showed a nominal protective effect [odds ratio (OR) 5 0.86
(0.79–0.94), P 5 0.0006] of the CC genotype on T2D risk, consistent with the previous study. By combining
all available data (n 5 49 279), we further confirmed a modest contribution of the BNP T-381C polymorphism
for protection against T2D [OR 5 0.86 (0.80–0.92), P 5 1.4 3 1025]. Potential confounders such as gender,
age, obesity status or family history were tested in 4335 T2D and 4179 normoglycemic subjects and they
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had no influence on T2D risk. This study provides further evidence of a modest contribution of the BNP T-
381C polymorphism in protection against T2D and illustrates the difficulty of unambiguously proving
modest-sized associations even with large sample sizes.
INTRODUCTION
The worldwide prevalence of type 2 diabetes (T2D) is projected
to nearly double by the year 2025 (1). T2D is associated with an
increased risk for nephropathy, end-stage renal disease, retino-
pathy, neuropathy, extremity amputations, cardiovascular
disease and an overall increase in mortality risk (2).
T2D results from a complex interaction between genetic and
environmental factors (3). So far, 17 genetic loci have been con-
vincingly associated with T2D risk (4). Replication is a challen-
ging but necessary step to validate new disease susceptibility
genetic variants (5). Some of the most promising associations
have indeed not been consistently replicated, suggesting that
the original associations were spurious (5). Further, obesity
status (6), family history of T2D (7), age (8), gender (9) and eth-
nicity (10) have been shown to modulate the effect of SNPs on
T2D risk and they should be taken into consideration for an ade-
quate interpretation of replication results.
Brain natriuretic peptide (BNP) is a member of the natriuretic
family. In humans, BNP acts mainly as a cardiac hormone, pro-
duced primarily by the atrium and ventricle (11). BNP is synthe-
tized in a pre-proBNP form in the ventricular myocardium, then
cleaved into proBNP, itself equimolarly cleaved into the bio-
logically active BNP and the inactive amino-terminal fragment
(NT-proBNP) (12,13). The measurement of BNP and
NT-proBNP concentrations are useful in establishing a diagno-
sis of heart failure. A variety of conditions can cause elevated
natriuretic peptide levels: heart failure, acute coronary syn-
dromes and renal dysfunction (14–16). Furthermore, the
plasma levels of these two peptides are specifically influenced
by age, gender and body mass index (BMI) (17,18). In the
context of obesity, BNP levels are lower than expected, both
in patients with and without heart failure (17,19). BNP is
involved in lipolysis in human fat cells through a cyclic guano-
sine monophosphate (cGMP) signalling pathway (20,21).
Recently, starting from the hypothesis that BNP could be
involved in metabolic diseases, Meirhaeghe et al. (22) studied
the implication of the BNP T-381C (rs198389) polymorphism
in T2D risk in 10 239 subjects and reported a protective role
of the CC genotype (versus CT þ TT) against T2D (P ¼
0.008). No study has confirmed this initial finding. This
prompted us to assess the contribution of the T-381C variant
to T2D in a large independent sample of European ancestry
(n ¼ 39 557), using case–control and family-based studies.
We then performed an updated meta-analysis of twelve inde-
pendent case–control studies totalling 49 279 subjects.
RESULTS
Case–control studies
Clinical characteristics of the study populations are summar-
ized in Table 1. We genotyped the BNP T-381C SNP in
four case–control cohorts: a first set of 4157 T2D patients
and 3628 controls of French origin, 178 T2D Swiss patients
and 551 normoglycemic (NG) Swiss subjects from Zurich
Table 1. Clinical characteristics of the study groups
Study Subjects n Sex ratio (men:women) Age at examination (years) Age at diagnosis (years) BMI (kg/m2)
Case–control studies French T2D subjects 4157 2,380:1,777 60.84+11.08 48.18+10.47 31.47+6.97
French NG controls 3628 1,503:2,125 54.38+9.60 — 25.52+5.96
Swiss 1 T2D subjects 178 78:100 50.06+9.24 NA 46.2+8.14
Swiss 1 NG controls 551 112:439 49.27+6.74 — 42.65+7.29
Swiss 2 T2D subjects 297 193:104 60.5+0.5 50.0+11.8 29.6+5.9
Swiss 2 NG controls 424 NA NA — NA
Austrian T2D subjects 426 254:172 56.67+9.6 NA 30.44+6.5
Austrian NG controls 352 287:65 49.15+5.84 — 26.2+4.0
DGI T2D casesa 1022 529:493 65.0+10 58.0+10 28.1+4.1
DGI NG controlsa 1075 540:535 58.0+10 — 27.6+3.7
FUSION T2D casesa 1161 653:508 63.4+11.2 53.0+12.0 29.8+6.1
FUSION NG controlsa 1174 574:600 64.0+11.7 — 26.8+5.0
DECODE T2D casesa 1405 829:576 68.4+12.5 55.1+12.4 30.1+5.4
DECODE NG controlsa 23 190 7,313:15,877 59.7+18.2 — 26.8+5.0
Family-based study T2D grand-parents 13 8:5 71.8+9.0 54.9+10.6 26.3+3.8
NG grand-parents 21 9:12 79.5+8.9 — 26.9+6.1
T2D parents 91 42:49 61.4+16.0 49.4+15.4 26.4+5.8
NG parents 54 19:35 72.0+9.7 — 25.9+4.3
T2D offspring 430 207:223 59.3+9.9 47.6+10.6 27.0+4.6
NG offspring 87 27:60 57.4+10.0 — 25.1+4.1
Data are mean+SD. T2D, type 2 diabetes; NG, normoglycemic; DGI, Diabetes Genetics Initiative; FUSION, Finland-United States Investigation of
NIDDM Genetics; NA, not available.
aImputed genotypic data.
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(set 1), all of them recruited for obesity surgery, an indepen-
dently ascertained cohort from Switzerland, containing 297
Swiss T2D patients and 424 anonymous blood donors from
CHUV of Lausanne (set 2), a cohort of 426 T2D and 352
Austria control subjects recruited in the area of Salzburg in
Austrian. We also used imputed data from three studies. We
used data from DIAGRAM, a recent meta-analysis of genome-
wide association studies (23). Because a part of the Wellcome
Trust Case Control Consortium (WTCCC) data was included
in the original study, we only used data from Diabetes Gen-
etics Initiative (DGI) (24), Finland-United States Investigation
of NIDDM Genetics (FUSION) (25) and DECODE genetics
(26,27) studies. We tested the impact of the BNP T-381C
SNP on T2D in these seven independent case–control
studies, but some of them were underpowered [statistical
power of 15–93% to detect the effect (odds ratio, OR ¼
0.85) previously reported (22)]. Only one of these studies ana-
lyzed alone showed an association between the BNP T-381C
polymorphism and risk for T2D: the DECODE study [OR ¼
0.77 (0.66–0.91), P ¼ 0.002 under a recessive model]. The
results from the seven case–control analyses are summarized
in Table 2. This result was expected, since only two of the
seven studies (4157 T2D and 3628 controls of French origin
and 1405 T2D and 23 190 controls of Icelandic origin)
achieved a statistical power .80% (93 and 81%, respect-
ively). To increase statistical power, we therefore combined
the seven case–control studies (n ¼ 39 040) in a meta-analysis
and we observed a nominal protective effect [OR ¼ 0.86
(0.79–0.94), P ¼ 0.0006] of the CC genotype on T2D
risk under a recessive model. This was consistent with a
statistical power of 100% to observe the effect (OR ¼ 0.85)
originally described (22). By using dominant or additive
models, we did not find more significant results than
with the recessive model (data not shown). Neither genetic
heterogeneity (P ¼ 0.71) between studies nor publication
bias (P ¼ 0.99) was observed for this meta-analysis.
Heterogeneity with confounding variables
We then assessed the association of the BNP T-381C poly-
morphism with T2D with possible confounding variables
such as obesity status, family history of T2D, age and
gender (6–9). For these analyses, only the French and Swiss
(set 1) subjects with documented data were used (4335 T2D
and 4179 NG subjects). No heterogeneity was found
between the French and Swiss (set 1) populations (P ¼
0.20), so we combined them for further analyses. Subgroup
analyses did not show any association of these confounding
variables with T2D (0.31 , P , 0.99, Materials and
Methods and Supplementary Material, Table S1A). Case-only
analyses of T2D patients after stratification for obesity status,
family history of T2D, age of diagnosis and gender did not
show any significant differences in the genotypic distribution
(P . 0.05, Supplementary Material, Table S1B).
Family-based association studies
We also performed family-based association studies that are
robust to population stratification (28,29). We genotyped the
BNP T-381C SNP in 291 pedigrees selected for T2D (179
T2D subjects were overlapping with the first previously
described French case–control design). Clinical character-
istics of the family-based study are described in Table 1. We
observed no distortion of transmission of the T risk allele in
affected offspring (in 105 informative pedigrees,
Z-score ¼ 20.46, P ¼ 0.65).
Table 2. Genotypic distributions and ORs for the BNP T-381C polymorphism and T2D among case–control studies
n OR [95% CI], P-value
TT TC CC OR additive OR recessive OR dominant
French study
Controls 1281 1734 613 — — —
Cases 1410 2059 688 0.98 [0.91–1.06], 0.71 0.93 [0.81–1.08], 0.35 1.01 [0.90–1.13], 0.85
Swiss 1 study
Controls 184 266 101 — — —
Cases 65 87 26 0.87 [0.67–1.12], 0.28 0.75 [0.46–1.24], 0.27 0.87 [0.60–1.27], 0.48
Swiss 2 study
Controls 154 205 65 — — —
Cases 112 142 43 0.95 [0.77–1.18], 0.67 0.93 [0.62–1.42], 0.75 0.94 [0.69–1.28], 0.7
Austrian study
Controls 123 159 70 — — —
Cases 138 211 77 1.01 [0.83–1.24], 0.88 0.89 [0.62–1.27], 0.52 1.12 [0.83–1.51], 0.45
DGI study
Controls 424 495 156 — — —
Cases 408 467 147 0.96 [0.83–1.12], 0.65 0.93 [0.67–1.29], 0.69 0.96 [0.76–1.19], 0.69
FUSION study
Controls 468 531 175 — — —
Cases 482 534 145 0.92 [0.82–1.04], 0.10 0.82 [0.64–1.05], 0.11 0.94 [0.80–1.12], 0.51
DECODE study
Controls 8520 10 962 3708 — — —
Cases 542 681 182 0.88 [0.81–0.97], 0.072 0.77 [0.66–0.91], 0.002 0.90 [0.79–1.02], 0.09
P-values adjusted for age, gender and BMI.
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Meta-analysis
Finally, we combined our current results (seven case–control
studies, n ¼ 39 040) with the five case–control studies from
Meirhaeghe et al. (22) in a meta-analysis of twelve studies
(n ¼ 49 279). We detected a modest protective effect of the
BNP-381CC genotype on T2D under a recessive model
[OR ¼ 0.86 (0.80–0.92), P ¼ 1.4  1025; Fig. 1]. Neither
genetic heterogeneity (P ¼ 0.50) between studies nor publi-
cation bias (P ¼ 0.31) was observed for this overall
meta-analysis.
DISCUSSION
Recently, Meirhaeghe et al. (22) proposed that the BNP
T-381C SNP may protect against T2D in European popu-
lations. Our data, supported by cross-sectional case–control
designs and a family-based study, showed a significant associ-
ation of the BNP T-381C polymorphism with T2D in only one
individual case–control study. However, by combining our
seven case–control studies in a meta-analysis, we observed
a modest protective effect [OR ¼ 0.86 (0.79–0.94), P ¼
0.0006] against T2D. Using all the available published
case–control data from twelve studies (n ¼ 49 279) in an
overall meta-analysis, we confirmed further this effect with
T2D [OR ¼ 0.86 (0.80–0.92), P ¼ 1.4  1025].
Previous works in the field of T2D genetics (e.g. PPARG
Pro12Ala, KCNJ11 E23K and WFS1 rs10010131) have
shown the value of large scale meta-analyses to conclude
about a true association, even if some individual studies
were negative (30–32). Although our data provide additional
confidence for a role for BNP, it remains below the conclusive
thresholds of association usually proposed (P, 1027), despite
a large sample size (n ¼ 49 279) (33). Nevertheless, the con-
sistent direction of effect observed in the twelve case–
control studies for this association between BNP rs198389
and T2D protection is striking (Fig. 1). Given this observation
and the low level of between-study heterogeneity for the
twelve study meta-analysis (P ¼ 0.50), we are hopeful
that future studies and updated larger meta-analyses will defi-
nitively confirm the association signal. Of note, it remains
theoretically possible that a true association (especially in
presence of between-study heterogeneity), may not be able
to be replicated with consistency, no matter how large the
studies (34).
Associations of genetic polymorphisms with T2D risk can
be modulated by different confounding factors, such as
family background, age, gender and obesity status (6–9). As
recently reported for the K121Q polymorphism in ENPP1
(35), the lack of replication for its association with T2D in
individual studies may be due, in part, to heterogeneity
between studies. Our data however exclude a major role of
confounding variables for the BNP T-381C polymorphism
and T2D risk.
To confirm a potential effect of the BNP T-381C functional
variation (22) in T2D susceptibility, the physiological role of
the BNP protein should be considered. BNP is a relevant can-
didate gene in energy metabolism and metabolic diseases, as it
is a member of the natriuretic family involved in the regulation
of blood pressure and blood volume (36), as well as in the
control of lipolysis in human fat cells (20). As previously
reported (22), the I-381C allele was associated with higher
plasma BNP concentrations and higher BNP promoter activity
in reporter gene assays, suggesting that relatively higher BNP
expression may protect against T2D. However, the emerging
genetic architecture of T2D strongly suggests that T2D sus-
ceptibility genes act predominantly through reduced beta-cell
function (37,38) and marginally by insulin action (30,39)
and up to now, no results have been published on a link
between BNP and beta-cell function or insulin action.
Further investigations are needed to understand the role of
BNP in the complex molecular and physiological mechanisms
involved in T2D.
In conclusion, the BNP T-381C SNP may have a modest
effect in T2D-susceptibility. This study illustrates the diffi-
culty of unambiguously proving association even with a
large sample size (n ¼ 49 279). Although no universal
threshold can be specified for statistical significance in all cir-
cumstances (28), our results clearly demonstrate the need for
multiple-replication, large-scale meta-analysis studies and
the use of stringent statistic thresholds in genetic association
reports before concluding about a true association signal.
Further investigation in additional populations of European
ancestry is therefore of interest for the BNP T-381C SNP.
A recent report showed a strong association between several
gene variants at the NPPA–NPPB/BNP locus and plasma
atrial natriuretic peptide, blood pressure or hypertension
(especially the rs63279 in strong linkage disequilibrium
(r2 ¼ 0.87 in HAPMAP CEU) with the T-381C SNP) (40).
Beyond the genetic study of the BNP T-381C SNP, these
data encourage us to investigate the full common SNP vari-
ation at the NPPA–NPPB/BNP in relation with glucose
homeostasis and T2D risk.
MATERIALS AND METHODS
Subjects
The study protocol was approved by local Ethics Committees
and an informed consent was obtained from each subject
before participating in the studies. Glycaemic status was
Figure 1. Meta-analysis of the association between BNP T-381C polymorph-
ism and T2D risk. The meta-analysis includes 37 040 controls and 12 239 T2D
cases. Summary illustrates the final OR under a recessive model; 95% CI is
included in the pictogram.
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defined according to 1997 American Diabetes Association
criteria (41): NG, defined as fasting glucose , 6.1 mmol/l
and T2D, defined as fasting plasma glucose  7.0 mmol/l
and/or treatment by glucose lowering agents. All cases were
either diagnosed with T2D or currently being treated for
T2D. All control subjects were NG with an age at diagnosis
40 or more years.
Study I: original case–control design. The 4157 T2D cases
and 3628 NG controls were French caucasians. They were
recruited in different centres in France. For the T2D subjects:
1922 were patients from the Endocrinology–Diabetology
Department at Corbeil-Essonnes Hospital, 726 were recruited
by the CNRS UMR8090 Unit and 1509 came from the DIA-
B2.NEPHRO.GENE study (42). For the NG subjects: 1882
were participants of the D.E.S.I.R. prospective study (43),
853 were recruited by the CNRS-IPL and 893 came from
the SUVIMAX (Supplementation en Vitamines et Mine´raux
Antioxidant) prospective cohort (44).
Study II: Swiss 1 replication cohort. We also genotyped 729
Swiss (178 cases and 551 controls), all of them were obese and
recruited after gastric surgery in Zurich (45).
Study III: Swiss 2 replication cohort. To confirm the find-
ings of studies I and II, we genotyped 297 additional Swiss
T2D patients and 424 control subjects ascertained from anon-
ymous healthy blood donors (CHUV of Lausanne).
Study IV: Austrian replication cohort. Four hundred and
twenty-six Austrian individuals with T2D recruited from dia-
betes outpatient clinics of the Landeskliniken Salzburg and
the Hallein Hospital and 352 Austrian control subjects from
the Salzburg Atherosclerosclerosis Prevention Program in
Subjects at High Individual Risk (SAPHIR) (46) were also
genotyped.
Study V: DGI and FUSION replication cohorts. We
included 1022 T2D cases and 1075 NG controls from the
DGI stage 1 of Swedish and Finnish origin (24). The
FUSION stage 1 sample had 1161 Finnish T2D cases and
1174 Finnish normal glucose-tolerant controls (25).
Study VI: DECODE genetics replication cohort. The
recruitment of the 1405 T2D cases and the 23 190 controls
from Icelandic origin has been described previously (26,27).
Study VII: T2D-selected pedigrees. In addition, we geno-
typed 291 French pedigrees recruited by UMR8090 for famil-
ial association tests. These families included 820 individuals,
of whom 534 presented with T2D, 124 were glucose intolerant
and 162 were NG subjects.
Genotyping
The BNP T-381C SNP was genotyped using the TaqMan tech-
nology (Applied Biosystems). Conditions for the TaqMan
reaction were 958C for 10 min and followed by 50 cycles of
958C for 15 s, 608C for 1 min.
Quality controls
The genotypic distribution of BNP T-381C SNP was in
Hardy–Weinberg equilibrium (P. 0.05) for all case–
control studies. There was a genotyping success rate of 98%,
and a concordance rate of 100% when analyzing 384
duplicated DNA samples. Genotyping was also controlled in
familial designs, using the PedCheck program (47). In
pedigrees with T2D, we observed one incompatibility in 291
pedigrees.
Statistical analysis
The DeFinetti program was used to test the deviation from
Hardy–Weinberg equilibrium (http://linkage.rockefeller.edu).
The Woolf test was applied to assess the genotypic heterogen-
eity between Swiss and French populations. The statistical
power was calculated with the QUANTO software, using the
total number of cases and controls, the current prevalence of
T2D in France (3.06% as reported by ALFEDIAM: http://
www.alfediam.org), the OR resulting from the first
meta-analysis (22) and an alpha-level P-value of 0.05. For
the family-based association test, we used the FBAT
program (Family Based Association Testing software). The
association with T2D was estimated using a logistic regression
model adjusted for age, gender and BMI. For the
meta-analysis, fixed-effect summary estimates were calculated
for a recessive model using the ‘rmeta’ and ‘meta’packages of
the R-Project (http://www.r-project.org). Subgroup analyses
shown in Supplementary Material, Table S1A were done as
followed: obese (BMI  30 kg/m2) T2D patients versus
obese NG controls, non-obese (BMI , 30 kg/m2) T2D sub-
jects versus non-obese NG subjects, T2D subjects with or
without familial T2D history versus the whole NG control
sample, T2D subjects with young onset T2D ( 48 years) or
with late onset T2D (. 48 years) versus the whole NG
control subset and finally T2D men versus NG men and
T2D women versus NG women. We used the recessive
model as previously proposed (22). However, the additive
and dominant models are presented in Table 2. We also
used Egger’s regression method to test for publication bias
(48). SPSS (version 14.0.2) and R (version 2.5.0) software
were used for general statistical analyses.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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